Seeking Alpha
View as an RSS Feed

Medical Stock Analyst  

View Medical Stock Analyst's Comments BY TICKER:
Latest  |  Highest rated
  • Biotech Weekly: Small Cap Biotechs Under $1 Billion Market Cap To Watch Into ASCO 2015 [View article]
    Happens to have great Pipeline..with Onapristone showing activity in multiple tumor types endometrial, prostate and breast cancer. Current extended release formulation has shown no safety issue so far..here is the link http://bit.ly/1H0vJsG
    May 6, 2015. 06:23 AM | 2 Likes Like |Link to Comment
  • Biotech Weekly: Small Cap Biotechs Under $1 Billion Market Cap To Watch Into ASCO 2015 [View article]
    Amazing how many posters here just to flog their own stocks...meanwhile ARNI ran up a cool 50% on this article. Never get married to a stock..go where you make $$
    May 5, 2015. 06:40 PM | 1 Like Like |Link to Comment
  • Significant Sell-Off Could Occur For Akebia Therapeutics At Lockup Expiration [View article]
    2 issues that make major sell-off less likely is data is due at the earliest 15 days post-lockup expiration and very likely positive given that drug has passed several phase 2 studies already.
    Sep 4, 2014. 09:08 AM | Likes Like |Link to Comment
  • Celldex After CDX-1135 - What's The Outlook? [View article]
    $1.1b valuation at $13.30 pps with no revenues or approved product is undervalued?

    CLDX is a promising company but carries one of the most ridiculous valuations in biotech. Period.
    May 27, 2014. 07:06 AM | 3 Likes Like |Link to Comment
  • Northwest Biotherapeutics (NWBO, $6.06, Buy): Comments On First Interim Look At DCVax-L Trial And Recent Weakness In The Stock  [View instapost]
    Any comments on the Feuerstein-Ratain Rule for oncology stocks?
    Mar 10, 2014. 06:55 AM | Likes Like |Link to Comment
  • Ico Therapeutics: Near-Term Catalyst Presents Enormous Upside [View article]
    Squalamine was developed by Granera and proved inferior to both Lucentris and Granera in treating wet AMD. Granera went out of business and OHRP paid $200,000 for the product. The same product that will ostensibly be better than eylea?
    Mar 1, 2014. 12:35 PM | Likes Like |Link to Comment
  • Halozyme announces $100M stock offering, shares -3.8% AH [View news story]
    So if I get this right...an offering indicates confidence and higher likelihood of buyout????
    Feb 3, 2014. 08:42 PM | Likes Like |Link to Comment
  • Evoke Pharma May Be One Of The Safest Biotech Bets Of 2014 [View article]
    Company loses all credibility when they issue a PR like they did yesterday..the study wasn't even theirs but some paper written and published in December. The way these things work I won't be surprised if they use this opportunity to raise funds.
    Jan 23, 2014. 09:12 AM | 1 Like Like |Link to Comment
  • Spyglass Resources: 3 Different Insiders Have Purchased Shares During The Last 30 Days [View article]
    Markus, check out SYN where Dr R. Kirkman just purchased $2.5 million shares in open market on 12/17..they have interesting pre-clinical drugs in the pipeline
    Dec 20, 2013. 05:57 PM | 1 Like Like |Link to Comment
  • Following Smart Money: Baker Brothers LLC Investments In 2013 And Beyond [View article]
    Some advice to a lot of the posters here..it reeks of desperation to use a PGNX specific article to promote your own pet-peeve unrelated bios
    Dec 19, 2013. 09:10 AM | Likes Like |Link to Comment
  • Amarin: Game Over For Current Shareholders Until Further Notice [View article]
    $400 million mkt cap at $2 is still grossly overvalued. Will eventually sink to under $1 imho.
    Oct 29, 2013. 09:01 AM | 1 Like Like |Link to Comment
  • Amarin And The Universal Biotech Catastrophe Playbook [View article]
    Biotech retail investors are such "sitting ducks" in this market it's embarrasing.
    Oct 23, 2013. 06:39 PM | Likes Like |Link to Comment
  • Zalicus Is A Promising Biotech With Echoes Of Acadia Pharmaceuticals [View article]
    I believe fear of RS is main reason this company is even trading at these levels. If trials are successful, r/s is nothing but a footnote in the company's history.
    Sep 23, 2013. 05:55 AM | Likes Like |Link to Comment
  • Zalicus Is A Promising Biotech With Echoes Of Acadia Pharmaceuticals [View article]
    I bought ACAD at $2.30 when not too many people had anything good to say about it. I have no problem owning Zalicus at these levels knowing I face a possible 100% downside versus 200-300% upside in the short term. High risk/ high reward.
    Sep 20, 2013. 03:02 PM | 2 Likes Like |Link to Comment
  • AcelRx Pharmaceuticals To Submit NDA By End Of September, May Be Acquired Soon [View article]
    Scott, I don't see how it helps anyone when you do a "broadside" about Zalicus being poorly managed without caring to explain yourself other than to get the article listed under ZLCS ticker symbol (a high volume ticker).
    Sep 20, 2013. 09:09 AM | 3 Likes Like |Link to Comment
COMMENTS STATS
52 Comments
33 Likes